Analysts: Allergan’s Phase II Trial Released Early and 3 More Research Notes to Browse

Allergan (NYSE:AGN): BMO Capital points out that Stage 3 of Allergan’s phase II trial for its anti-VEGF DARPin product was released on sooner than expected. BMO sees this as a positive for the company and has an Outperform rating on the stock with a $118 price target.